Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals.
María Sánchez-AzofraInmaculada FernándezMaría L García-BueyLourdes Domínguez-DomínguezConrado M Fernández RodríguezAntonio ManceboLucía BonetPablo RyanFrancisco GeaAntonio Díaz-SánchezMarian García-MayorLuz Martín-CarboneroPilar CastilloMaría L ManzanoLeticia González-MorenoFederico PulidoMaría L GutiérrezJosé M MorenoIrene M García-AmengualGuillermo Cuevas TascónAntonio GuerreroMiguel Rivero-FernándezMaría E PortalesMaría L MontesAntonio OlveiraPublished in: Liver international : official journal of the International Association for the Study of the Liver (2021)
In a large, well-defined cohort of patients with baseline hepatitis C stage-3 fibrosis, the incidence of primary liver tumours was low after sustained virological response and far from the threshold for cost-effectiveness of screening, except in males older than 55 years.